Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8735176 | 0.87 | BTK (0.64) | BTK | |
| SCHEMBL15578691 | 0.86 | BTK (0.53) | BTK | |
| SCHEMBL13835217 | 0.83 | BTK (0.63) | BTK | |
| SCHEMBL1725849 | 0.82 | BTK (0.68) | BTK | |
| SCHEMBL15577348 | 0.82 | BTK (0.48) | BTK | |
| SCHEMBL13570103 | 0.81 | BTK (0.57) | BTK | |
| SCHEMBL13835249 | 0.81 | BTK (0.52) | BTK | |
| SCHEMBL13834844 | 0.80 | BTK (0.51) | BTK | |
| SCHEMBL13975743 | 0.79 | BTK (0.86) | BTK | |
| SCHEMBL13861495 | 0.79 | BTK (0.86) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499548-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499548-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499548-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150210704-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210704-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210704-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| EP-2895473-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. Hoffmann-La Roche AG (CH) | 2015-07-22 | — | — | EP | disclosed |
| WO-2014040965-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-20 | — | — | WO | disclosed |
| WO-2014040965-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210704-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.